Sign in or create an account to add this stock to your watchlist.
About Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596
Debt
Debt-to-Equity Ratio0.33
Current Ratio3.35
Quick Ratio2.86
Price-To-Earnings
Trailing P/E Ratio22.70
Forward P/E Ratio18.65
P/E Growth1.07
Sales & Book Value
Annual Sales$3.55 billion
Price / Sales7.34
Cash Flow$7.9095 per share
Price / Cash14.81
Book Value$40.96 per share
Price / Book2.86
Profitability
EPS (Most Recent Fiscal Year)$5.16
Net Income$443.30 million
Net Margins14.46%
Return on Equity13.70%
Return on Assets9.00%
Miscellaneous
Employees2,525
Outstanding Shares222,500,000
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
How will Alexion Pharmaceuticals' stock buyback program work?
Alexion Pharmaceuticals declared that its board has initiated a stock repurchase program on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 3.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals (NASDAQ:ALXN) released its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.18. The biopharmaceutical company had revenue of $930.90 million for the quarter, compared to analysts' expectations of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The business's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.38 earnings per share. View Alexion Pharmaceuticals' Earnings History.
When is Alexion Pharmaceuticals' next earnings date?
What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?
Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.
What price target have analysts set for ALXN?
21 brokers have issued 1-year target prices for Alexion Pharmaceuticals' shares. Their forecasts range from $120.00 to $180.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $156.8571 in the next year. View Analyst Ratings for Alexion Pharmaceuticals.
What are Wall Street analysts saying about Alexion Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alexion beat on both earnings and sales in the first quarter of 2018 driven by strength of blockbuster drug Soliris which continues to perform well. The FDA approval for the generalized myasthenia gravis indication has boosted sales further. The prospects of ALXN1210 looks good too given the positive data from the switch study and in treatment-naïve patients. The increase in guidance was also encouraging. Meanwhile, Alexion is looking to diversify its portfolio and reduce its dependence on Soliris. The recently announced Wilson deal will strengthen Alexion’s rare disease pipeline with a late-stage candidate, WTX101 which is currently in phase III for the treatment of Wilson disease. Shares of the company have performed better than the industry in the last six months. However, the company relies heavily on Soliris for growth and sales of the same will be impacted by ramp-up of ALXN1210 trials. Pricing will also imapct sales." (5/2/2018)
- 2. JPMorgan Chase & Co. analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY) and Shiseido (SSDOY).
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the folowing people:
- Dr. Ludwig N. Hantson, CEO & Director (Age 55)
- Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
- Ms. Julie O'Neill MBA, Exec. VP of Global Operations (Age 62)
- Mr. John B. Moriarty Jr., Former Exec. VP & Gen. Counsel (Age 50)
- Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)
Has Alexion Pharmaceuticals been receiving favorable news coverage?
Headlines about ALXN stock have been trending somewhat positive on Thursday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.73 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Alexion Pharmaceuticals' major shareholders?
Alexion Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.03%), Northern Trust Corp (1.28%), Franklin Resources Inc. (1.00%), BB Biotech AG (0.63%), Wells Fargo & Company MN (0.59%) and Eaton Vance Management (0.52%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Paul J Clancy and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.
Which major investors are selling Alexion Pharmaceuticals stock?
ALXN stock was sold by a variety of institutional investors in the last quarter, including Natixis, Amundi Pioneer Asset Management Inc., State of Tennessee Treasury Department, Franklin Resources Inc., American Century Companies Inc., Federated Investors Inc. PA, Prudential Financial Inc. and Nuveen Asset Management LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.
Which major investors are buying Alexion Pharmaceuticals stock?
ALXN stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, PointState Capital LP, Redmile Group LLC, Westfield Capital Management Co. LP, FIL Ltd, Braun Stacey Associates Inc., Wells Fargo & Company MN and SG Americas Securities LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.
How do I buy shares of Alexion Pharmaceuticals?
Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexion Pharmaceuticals' stock price today?
One share of ALXN stock can currently be purchased for approximately $117.14.
How big of a company is Alexion Pharmaceuticals?
Alexion Pharmaceuticals has a market capitalization of $26.48 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.
How can I contact Alexion Pharmaceuticals?
Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.
MarketBeat Community Rating for Alexion Pharmaceuticals (ALXN)
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alexion Pharmaceuticals (NASDAQ:ALXN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
21 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $156.8571, suggesting that the stock has a possible upside of 33.91%. The high price target for ALXN is $180.00 and the low price target for ALXN is $120.00. There are currently 1 hold rating and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.95 | 2.95 | 2.95 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $156.8571 | $156.5238 | $153.1905 | $154.8636 |
| Price Target Upside: | 33.91% upside | 45.16% upside | 41.06% upside | 14.54% upside |
Alexion Pharmaceuticals (NASDAQ:ALXN) Consensus Price Target History
Alexion Pharmaceuticals (NASDAQ:ALXN) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Alexion Pharmaceuticals (NASDAQ:ALXN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.35%
Institutional Ownership Percentage: 92.40%
Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/30/2018 | Christopher J Coughlin | Director | Buy | 10,000 | $120.79 | $1,207,900.00 | 26,333 |  |
| 2/28/2018 | Heidi L Wagner | SVP | Sell | 698 | $119.35 | $83,306.30 | | |
| 2/28/2018 | Julie O'neill | EVP | Sell | 1,625 | $119.83 | $194,723.75 | | |
| 2/8/2018 | Heidi L Wagner | SVP | Sell | 1,774 | $116.31 | $206,333.94 | 47,212 | |
| 2/8/2018 | John B Moriarty | EVP | Sell | 3,363 | $115.70 | $389,099.10 | 71,400 | |
| 2/8/2018 | Ludwig Hantson | CEO | Sell | 13,245 | $116.31 | $1,540,525.95 | 131,425 | |
| 2/8/2018 | Paul J Clancy | CFO | Sell | 6,079 | $116.31 | $707,048.49 | 95,093 | |
| 2/5/2018 | Heidi L Wagner | SVP | Sell | 655 | $117.26 | $76,805.30 | 32,635 | |
| 2/5/2018 | John B Moriarty | EVP | Sell | 1,261 | $117.26 | $147,864.86 | 20,210 | |
| 1/2/2018 | Ludwig Hantson | CEO | Sell | 2,553 | $121.63 | $310,521.39 | 36,172 | |
| 10/2/2017 | Heidi L Wagner | SVP | Sell | 120 | $140.00 | $16,800.00 | | |
| 9/5/2017 | Ann M Veneman | Director | Sell | 835 | $145.81 | $121,751.35 | 5,480 | |
| 9/5/2017 | Julie O'neill | EVP | Sell | 4,375 | $145.44 | $636,300.00 | 26,092 | |
| 8/28/2017 | Julie O'neill | EVP | Sell | 11,160 | $140.00 | $1,562,400.00 | 26,704 | |
| 7/31/2017 | Ann M Veneman | Director | Sell | 700 | $137.74 | $96,418.00 | 6,315 | |
| 6/15/2017 | Bros. Advisors Lp Baker | Director | Buy | 660,779 | $117.33 | $77,529,200.07 | | |
| 6/14/2017 | Bros. Advisors Lp Baker | Director | Buy | 1,348,955 | $116.32 | $156,910,445.60 | | |
| 6/14/2017 | Ludwig Hantson | CEO | Buy | 10,000 | $116.72 | $1,167,200.00 | 38,725 | |
| 3/1/2017 | Clare Carmichael | EVP | Sell | 2,179 | $131.66 | $286,887.14 | 33,980 | |
| 3/1/2017 | Heidi L Wagner | SVP | Sell | 994 | $131.65 | $130,860.10 | 29,646 | |
| 3/1/2017 | Leonard Bell | Director | Sell | 3,978 | $131.96 | $524,936.88 | 391,910 | |
| 2/28/2017 | Carsten Thiel | EVP | Sell | 125 | $74.52 | $9,315.00 | 30,197 | |
| 2/28/2017 | Edward Miller | SVP | Sell | 590 | $131.48 | $77,573.20 | 15,214 | |
| 2/28/2017 | Leonard Bell | Director | Sell | 2,738 | $131.71 | $360,621.98 | 391,910 | |
| 2/27/2017 | Edward Miller | SVP | Sell | 260 | $131.20 | $34,112.00 | 15,214 | |
| 2/27/2017 | John B Moriarty | EVP | Sell | 612 | $131.20 | $80,294.40 | 45,864 | |
| 2/9/2017 | John B Moriarty | EVP | Sell | 167 | $126.84 | $21,182.28 | 46,476 | |
| 2/9/2017 | Leonard Bell | Director | Sell | 246 | $126.84 | $31,202.64 | 394,648 | |
| 2/7/2017 | Heidi L Wagner | SVP | Sell | 1,932 | $125.97 | $243,374.04 | 30,241 | |
| 2/7/2017 | John B Moriarty | EVP | Sell | 3,538 | $125.79 | $445,045.02 | 46,801 | |
| 2/7/2017 | Leonard Bell | Director | Sell | 8,725 | $125.97 | $1,099,088.25 | 395,979 | |
| 1/10/2017 | Leonard Bell | Director | Sell | 100 | $144.99 | $14,499.00 | 403,719 | |
| 1/9/2017 | Leonard Bell | Director | Sell | 40,065 | $138.48 | $5,548,201.20 | 438,497 | |
| 1/5/2017 | Alvin S Parven | Director | Sell | 22,659 | $138.35 | $3,134,872.65 | 14,305 | |
| 12/12/2016 | John B Moriarty | EVP | Sell | 1,044 | $118.61 | $123,828.84 | 50,181 | |
| 12/9/2016 | Carsten Thiel | EVP | Sell | 2,308 | $130.00 | $300,040.00 | 30,433 | |
| 11/14/2016 | Heidi L Wagner | SVP | Sell | 59 | $115.10 | $6,790.90 | 31,936 | |
| 11/4/2016 | Leonard Bell | Director | Sell | 37,317 | $140.38 | $5,238,560.46 | 440,936 | |
| 10/31/2016 | Leonard Bell | Director | Sell | 1,300 | $135.28 | $175,864.00 | 406,589 | |
| 10/14/2016 | Carsten Thiel | EVP | Sell | 4,584 | $120.28 | $551,363.52 | 32,741 | |
| 10/3/2016 | Carsten Thiel | EVP | Sell | 29 | $122.41 | $3,549.89 | 37,325 | |
| 10/3/2016 | Heidi L Wagner | SVP | Sell | 120 | $122.41 | $14,689.20 | 31,995 | |
| 9/13/2016 | Carsten Thiel | EVP | Sell | 3,225 | $128.67 | $414,960.75 | 40,354 | |
| 9/9/2016 | Edward Miller | SVP | Sell | 367 | $128.32 | $47,093.44 | 16,519 | |
| 9/6/2016 | Carsten Thiel | EVP | Sell | 1,000 | $125.94 | $125,940.00 | 40,579 | |
| 9/2/2016 | Julie O'neill | EVP | Sell | 650 | $126.29 | $82,088.50 | 35,384 | |
| 8/30/2016 | Clare Carmichael | EVP | Sell | 1,000 | $127.76 | $127,760.00 | 38,577 | |
| 8/22/2016 | Alvin S Parven | Director | Sell | 15,000 | $136.53 | $2,047,950.00 | 6,373 | |
| 8/15/2016 | Alvin S Parven | Director | Sell | 700 | $135.51 | $94,857.00 | 6,373 | |
| 8/8/2016 | Clare Carmichael | EVP | Sell | 165 | $137.14 | $22,628.10 | 39,577 | |
| 8/8/2016 | David Hallal | CEO | Sell | 332 | $137.14 | $45,530.48 | 189,266 | |
| 8/8/2016 | Heidi L Wagner | SVP | Sell | 222 | $137.14 | $30,445.08 | 32,115 | |
| 8/8/2016 | Leonard Bell | Director | Sell | 1,010 | $137.14 | $138,511.40 | 405,289 | |
| 8/8/2016 | Vikas Sinha | CFO | Sell | 277 | $137.14 | $37,987.78 | 178,463 | |
| 6/13/2016 | John B Moriarty | EVP | Sell | 918 | $135.72 | $124,590.96 | 51,360 | |
| 5/16/2016 | Martin Mackay | EVP | Sell | 4,097 | $139.20 | $570,302.40 | 42,706 | |
| 5/13/2016 | Heidi L Wagner | SVP | Sell | 53 | $138.65 | $7,348.45 | 32,337 | |
| 4/1/2016 | David Hallal | CEO | Sell | 1,414 | $135.88 | $192,134.32 | 189,632 | |
| 2/29/2016 | Clare Carmichael | EVP | Sell | 1,312 | $138.91 | $182,249.92 | 41,054 | |
| 2/29/2016 | David Hallal | CEO | Sell | 2,014 | $138.93 | $279,805.02 | 193,026 | |
| 2/29/2016 | Edward Miller | SVP | Sell | 329 | $138.91 | $45,701.39 | 17,215 | |
| 2/29/2016 | Leonard Bell | Director | Sell | 3,995 | $138.92 | $554,985.40 | 742,222 | |
| 2/29/2016 | Vikas Sinha | CFO | Sell | 1,122 | $138.91 | $155,857.02 | 179,862 | |
| 2/8/2016 | David Hallal | CEO | Sell | 11,297 | $140.50 | $1,587,228.50 | 173,026 | |
| 2/8/2016 | Heidi L. Wagner | SVP | Sell | 2,108 | $140.93 | $297,080.44 | 29,937 | |
| 2/8/2016 | Julie O'neill | EVP | Sell | 2,858 | $141.83 | $405,350.14 | 30,348 | |
| 2/8/2016 | Leonard Bell | Director | Sell | 15,872 | $139.58 | $2,215,413.76 | 746,192 | |
| 2/8/2016 | Vikas Sinha | CFO | Sell | 6,547 | $140.04 | $916,841.88 | 171,862 | |
| 2/5/2016 | Edward Miller | SVP | Sell | 1,051 | $143.02 | $150,314.02 | 14,215 | |
| 12/29/2015 | Leonard Bell | Director | Sell | 35,000 | $190.66 | $6,673,100.00 | 749,259 | |
| 12/17/2015 | Leonard Bell | Director | Sell | 70,000 | $187.69 | $13,138,300.00 | 749,259 | |
| 12/11/2015 | Ann M Veneman | Director | Sell | 895 | $187.48 | $167,794.60 | 3,252 | |
| 12/11/2015 | John B. Moriarty | EVP | Sell | 943 | $182.73 | $172,314.39 | 41,340 | |
| 12/8/2015 | Leonard Bell | Director | Sell | 70,000 | $188.20 | $13,174,000.00 | 849,088 | |
| 12/8/2015 | Saqib Islam | EVP | Sell | 950 | $190.00 | $180,500.00 | 36,385 | |
| 11/25/2015 | Leonard Bell | Director | Sell | 35,000 | $181.89 | $6,366,150.00 | 919,088 | |
| 10/26/2015 | Saqib Islam | EVP | Sell | 1,558 | $168.44 | $262,429.52 | 38,310 | |
| 9/9/2015 | Leonard Bell | Director | Sell | 1,050 | $180.10 | $189,105.00 | 919,088 | |
| 6/18/2015 | Leonard Bell | Director | Sell | 27,835 | $179.63 | $5,000,001.05 | | |
| 3/19/2015 | Leonard Bell | CEO | Sell | 15,952 | $188.07 | $3,000,092.64 | | |
| 3/2/2015 | Julie O'neill | EVP | Sell | 11,665 | $101.49 | $1,183,880.85 | | |
| 3/2/2015 | Leonard Bell | CEO | Sell | 1,230 | $180.34 | $221,818.20 | | |
| 2/10/2015 | Clare Carmichael | EVP | Sell | 1,490 | $171.15 | $255,013.50 | | |
| 2/10/2015 | David Hallal | COO | Sell | 1,980 | $171.15 | $338,877.00 | | |
| 2/10/2015 | Leonard Bell | CEO | Sell | 5,740 | $171.15 | $982,401.00 | | |
| 2/10/2015 | Vikas Sinha | CFO | Sell | 1,985 | $171.15 | $339,732.75 | | |
| 2/9/2015 | Clare Carmichael | EVP | Sell | 1,665 | $173.75 | $289,293.75 | | |
| 2/9/2015 | David Hallal | COO | Sell | 2,920 | $173.93 | $507,875.60 | | |
| 2/9/2015 | Leonard Bell | CEO | Sell | 8,660 | $173.98 | $1,506,666.80 | | |
| 2/9/2015 | Vikas Sinha | CFO | Sell | 2,703 | $174.18 | $470,808.54 | | |
| 2/4/2015 | David Hallal | COO | Sell | 1,373 | $174.18 | $239,149.14 | | |
| 2/4/2015 | Leonard Bell | CEO | Sell | 5,223 | $174.29 | $910,316.67 | | |
| 2/4/2015 | Vikas Sinha | CFO | Sell | 1,571 | $174.19 | $273,652.49 | | |
| 12/18/2014 | David Hallal | COO | Sell | 5,494 | $182.03 | $1,000,072.82 | | |
| 12/18/2014 | Leonard Bell | CEO | Sell | 30,415 | $179.73 | $5,466,487.95 | | |
| 12/18/2014 | Vikas Sinha | CFO | Sell | 5,493 | $182.08 | $1,000,165.44 | | |
| 12/9/2014 | Leonard Bell | CEO | Sell | 133,320 | $198.26 | $26,432,023.20 | | |
| 12/4/2014 | Clare Carmichael | SVP | Sell | 10,000 | $196.25 | $1,962,500.00 | | |
| 12/4/2014 | William R Keller | Director | Sell | 5,000 | $196.25 | $981,250.00 | | |
| 12/3/2014 | Vikas Sinha | CFO | Sell | 75,000 | $198.96 | $14,922,000.00 | | |
| 11/3/2014 | David Hallal | COO | Sell | 30,000 | $190.01 | $5,700,300.00 | | |
| 11/3/2014 | Martin Mackay | EVP | Sell | 9,375 | $191.52 | $1,795,500.00 | | |
| 11/3/2014 | Saqib Islam | SVP | Sell | 28,125 | $190.50 | $5,357,812.50 | | |
| 11/3/2014 | Vikas Sinha | CFO | Sell | 49,307 | $192.63 | $9,498,007.41 | | |
| 10/27/2014 | John B Moriarty | SVP | Sell | 10,000 | $189.49 | $1,894,900.00 | | |
| 10/27/2014 | Stephen P Squinto | EVP | Sell | 5,910 | $188.58 | $1,114,507.80 | | |
| 10/6/2014 | John B Moriarty | SVP | Sell | 10,000 | $179.00 | $1,790,000.00 | | |
| 10/3/2014 | Stephen P Squinto | EVP | Sell | 10,025 | $172.41 | $1,728,410.25 | | |
| 9/26/2014 | Leonard Bell | CEO | Sell | 60,000 | $165.12 | $9,907,200.00 | | |
| 9/24/2014 | Stephen P Squinto | EVP | Sell | 76 | $159.50 | $12,122.00 | | |
| 9/18/2014 | Leonard Bell | CEO | Sell | 44,435 | $160.60 | $7,136,261.00 | | |
| 9/10/2014 | Leonard Bell | CEO | Sell | 12,199 | $165.38 | $2,017,470.62 | | |
| 9/8/2014 | Leonard Bell | CEO | Sell | 197,801 | $165.32 | $32,700,461.32 | | |
| 8/27/2014 | Leonard Bell | CEO | Sell | 5,912 | $169.17 | $1,000,133.04 | | |
| 8/25/2014 | Andreas Rummelt | Director | Sell | 5,052 | $170.53 | $861,517.56 | | |
| 8/15/2014 | Leonard Bell | CEO | Sell | 70,000 | $167.99 | $11,759,300.00 | | |
| 8/13/2014 | Leonard Bell | CEO | Sell | 105,000 | $160.71 | $16,874,550.00 | | |
| 8/12/2014 | Leonard Bell | CEO | Sell | 80,458 | $160.16 | $12,886,153.28 | | |
| 8/4/2014 | David Hallal | EVP | Sell | 1,349 | $158.00 | $213,142.00 | | |
| 8/4/2014 | Leonard Bell | CEO | Sell | 5,145 | $157.88 | $812,292.60 | | |
| 8/4/2014 | Vikas Sinha | CFO | Sell | 1,525 | $157.82 | $240,675.50 | | |
| 7/30/2014 | Leonard Bell | CEO | Sell | 127,289 | $162.93 | $20,739,196.77 | | |
| 7/29/2014 | Leonard Bell | CEO | Sell | 1,200 | $164.93 | $197,916.00 | | |
| 7/28/2014 | Leonard Bell | CEO | Sell | 105,600 | $162.38 | $17,147,328.00 | | |
| 6/20/2014 | Leonard Bell | CEO | Sell | 90,280 | $163.60 | $14,769,808.00 | | |
| 6/12/2014 | Martin Mackay | EVP | Sell | 25,000 | $166.42 | $4,160,500.00 | | |
| 6/5/2014 | William R Keller | Director | Sell | 3,425 | $170.00 | $582,250.00 | | |
| 5/27/2014 | Leonard Bell | CEO | Sell | 70,000 | $166.16 | $11,631,200.00 | | |
| 5/20/2014 | Leonard Bell | CEO | Sell | 70,000 | $155.96 | $10,917,200.00 | 1,032,331 | |
| 5/14/2014 | Martin Mackay | EVP | Sell | 3,574 | $160.85 | $574,877.90 | 24,426 | |
| 5/13/2014 | Alvin Parven | Director | Sell | 12,276 | $160.78 | $1,973,735.28 | 4,840 | |
| 4/29/2014 | Leonard Bell | CEO | Sell | 70,000 | $156.20 | $10,934,000.00 | 1,032,331 | |
| 2/10/2014 | Stephen Squinto | EVP | Sell | 7,055 | $158.04 | $1,114,972.20 | 101,308 | |
| 2/7/2014 | David Hallal | EVP | Sell | 1,620 | $155.57 | $252,023.40 | 113,965 | |
| 2/7/2014 | Frank Wright | SVP | Sell | 1,098 | $155.57 | $170,815.86 | 19,670 | |
| 2/7/2014 | Joseph Madri | Director | Sell | 30,000 | $159.00 | $4,770,000.00 | 179,217 | |
| 2/7/2014 | Leonard Bell | CEO | Sell | 4,620 | $155.56 | $718,687.20 | 986,696 | |
| 2/4/2014 | Leonard Bell | CEO | Sell | 11,790 | $154.50 | $1,821,555.00 | 963,276 | |
| 2/4/2014 | Stephen Squinto | EVP | Sell | 36,989 | $155.12 | $5,737,733.68 | 94,818 | |
| 2/4/2014 | Vikas Sinha | CFO | Sell | 3,552 | $154.47 | $548,677.44 | 129,775 | |
| 1/29/2014 | Leonard Bell | CEO | Sell | 2,660 | $133.81 | $355,934.60 | 975,066 | |
| 1/29/2014 | Stephen Squinto | EVP | Sell | 1,118 | $133.31 | $149,040.58 | 103,068 | |
| 1/22/2014 | Leonard Bell | CEO | Sell | 156,436 | $140.80 | $22,026,188.80 | 977,726 | |
| 1/10/2014 | Leonard Bell | CEO | Sell | 19,155 | $134.98 | $2,585,541.90 | 1,031,957 | |
| 12/19/2013 | Leonard Bell | CEO | Sell | 175,000 | $126.38 | $22,116,500.00 | 1,031,957 | |
| 10/28/2013 | Stephen P Squinto | EVP | Sell | 41,037 | $124.06 | $5,091,050.22 | | |
| 10/28/2013 | Vikas Sinha | CFO | Sell | 50,000 | $122.97 | $6,148,500.00 | | |
| 9/16/2013 | Joseph Madri | Director | Sell | 30,000 | $115.00 | $3,450,000.00 | 179,217 | |
| 9/16/2013 | Leonard Bell | CEO | Sell | 3,500 | $115.00 | $402,500.00 | 1,026,293 | |
| 9/13/2013 | Stephen Squinto | EVP | Sell | 1,000 | $114.37 | $114,370.00 | | |
| 9/4/2013 | Leonard Bell | CEO | Sell | 1,850 | $110.07 | $203,629.50 | | |
| 9/3/2013 | Leonard Bell | CEO | Sell | 33,150 | $110.19 | $3,652,798.50 | 1,003,519 | |
| 8/30/2013 | Clare Carmichael | SVP | Sell | 1,237 | $107.58 | $133,076.46 | 9,463 | |
| 8/16/2013 | Leonard Bell | CEO | Sell | 140,000 | $106.08 | $14,851,200.00 | 1,036,669 | |
| 8/5/2013 | Leonard Bell | CEO | Sell | 2,919 | $116.87 | $341,143.53 | 1,176,669 | |
| 8/2/2013 | Stephen P Squinto | EVP | Sell | 14,125 | $115.33 | $1,629,036.25 | | |
| 7/30/2013 | Leonard Bell | CEO | Sell | 212,737 | $114.62 | $24,383,914.94 | | |
| 7/30/2013 | Stephen P Squinto | EVP | Sell | 1,120 | $110.86 | $124,163.20 | | |
| 7/12/2013 | David Hallal | EVP | Sell | 50,000 | $120.00 | $6,000,000.00 | | |
| 7/1/2013 | Stephen P Squinto | EVP | Sell | 44,125 | $94.97 | $4,190,551.25 | | |
| 5/22/2013 | R Douglas Norby | Director | Sell | 40,000 | $102.77 | $4,110,800.00 | | |
| 5/20/2013 | William R Keller | Director | Sell | 9,770 | $103.00 | $1,006,310.00 | | |
| 5/14/2013 | Leonard Bell | CEO | Sell | 31,113 | $105.74 | $3,289,888.62 | | |
| 5/13/2013 | Leonard Bell | CEO | Sell | 41,220 | $100.85 | $4,157,037.00 | | |
| 4/10/2013 | Leonard Bell | CEO | Sell | 26,700 | $100.24 | $2,676,408.00 | | |
| 2/4/2013 | Leonard Bell | CEO | Sell | 11,880 | $96.27 | $1,143,687.60 | | |
| 2/4/2013 | Stephen P Squinto | EVP | Sell | 2,572 | $95.68 | $246,088.96 | | |
| 2/4/2013 | Vikas Sinha | CFO | Sell | 3,483 | $95.81 | $333,706.23 | | |
| 1/15/2013 | Leonard Bell | CEO | Sell | 35,000 | $98.58 | $3,450,300.00 | | |
| 10/31/2012 | Patrice Coissac | SVP | Sell | 84,764 | $91.16 | $7,727,086.24 | | |
(Data available from 1/1/2013 forward)
Alexion Pharmaceuticals (NASDAQ ALXN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Insight into Alexion Pharmaceuticals’ Solid Product Performance
finance.yahoo.com - May 18 at 6:02 PM |
| Analyzing Alexion’s Cash Flows and Valuation Metrics
finance.yahoo.com - May 18 at 6:02 PM |
| Exploring the Promising Research Pipeline of Alexion Therapeutics
finance.yahoo.com - May 18 at 6:02 PM |
| Alexion Delivered a Solid Financial Performance in Q1 2018
finance.yahoo.com - May 18 at 6:02 PM |
| Analyzing Alexion’s Acquisition of Wilson Therapeutics
finance.yahoo.com - May 18 at 6:02 PM |
 | $980.63 Million in Sales Expected for Alexion Pharmaceuticals (ALXN) This Quarter
www.americanbankingnews.com - May 15 at 4:39 AM |
| Alexion Pharmaceuticals (ALXN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 15 at 1:22 AM |
| $1.68 Earnings Per Share Expected for Alexion Pharmaceuticals (ALXN) This Quarter
www.americanbankingnews.com - May 13 at 5:23 AM |
 | Alexion Pharmaceuticals (ALXN) Defended at RBC
www.streetinsider.com - May 10 at 5:59 PM |
 | Noteworthy Tuesday Option Activity: ALXN, USAT, FDX
www.nasdaq.com - May 8 at 5:41 PM |
| Alexion to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 8 at 5:41 PM |
| Christopher J. Coughlin Buys 10,000 Shares of Alexion Pharmaceuticals (ALXN) Stock
www.americanbankingnews.com - May 2 at 7:20 PM |
| Zacks Investment Research Downgrades Alexion Pharmaceuticals (ALXN) to Hold
www.americanbankingnews.com - May 2 at 12:25 PM |
| Edited Transcript of ALXN earnings conference call or presentation 26-Apr-18 2:00pm GMT
finance.yahoo.com - April 30 at 5:15 PM |
| Alexion Pharmaceuticals (ALXN) Price Target Increased to $173.00 by Analysts at Citigroup
www.americanbankingnews.com - April 30 at 9:31 AM |
 | Alexion Clears A Path For 2nd Generation PNH Drug
seekingalpha.com - April 30 at 8:22 AM |
 | BRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study
www.reuters.com - April 28 at 5:15 PM |
| Alexion Pharmaceuticals (ALXN) PT Set at $149.00 by Credit Suisse Group
www.americanbankingnews.com - April 28 at 9:38 AM |
| Analysts’ Recommendations for Vertex Pharmaceuticals
finance.yahoo.com - April 28 at 8:27 AM |
| Alexion Pharmaceuticals (ALXN) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - April 27 at 11:22 AM |
 | Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%
www.zacks.com - April 27 at 8:28 AM |
| Zacks: Brokerages Expect Alexion Pharmaceuticals (ALXN) Will Announce Quarterly Sales of $917.52 Million
www.americanbankingnews.com - April 27 at 2:38 AM |
| Alexion Pharmaceuticals (ALXN) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - April 26 at 6:50 PM |
| Alexion Pharma Q1 revenues up 7%; non-GAAP EPS up 22%; raises revenue guidance
seekingalpha.com - April 26 at 5:18 PM |
| Alexion Pharmaceuticals (ALXN) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 5:18 PM |
 | Alexion shares jump after company raises guidance
www.marketwatch.com - April 26 at 5:18 PM |
| Here's Why Alexion Pharmaceuticals Is Surging Today
finance.yahoo.com - April 26 at 5:18 PM |
| Boston-bound Alexion gets $2.5B stock jolt as earnings, drug trial impress
finance.yahoo.com - April 26 at 5:18 PM |
| Here's Why Alexion Pharmaceuticals Is Surging Today
finance.yahoo.com - April 26 at 5:18 PM |
| Alexion Rockets As New Drug Proves Itself Against Blockbuster Soliris
finance.yahoo.com - April 26 at 5:18 PM |
| Why Domino's Pizza, Advanced Micro Devices, and Alexion Pharmaceuticals Jumped Today
finance.yahoo.com - April 26 at 5:18 PM |
| Alexion Pharmaceuticals (ALXN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - April 26 at 10:58 AM |
| Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates
www.zacks.com - April 26 at 8:15 AM |
| Alexion Pharmaceuticals beats by $0.18, beats on revenue
seekingalpha.com - April 26 at 8:15 AM |
| Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study
finance.yahoo.com - April 26 at 8:15 AM |
| Alexion: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 8:15 AM |
| $1.48 EPS Expected for Alexion Pharmaceuticals (ALXN) This Quarter
www.americanbankingnews.com - April 25 at 5:10 PM |
| [$$] New Biotech Grabs Series A for Rare Disease Treatments
finance.yahoo.com - April 25 at 8:19 AM |
| Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season
finance.yahoo.com - April 24 at 5:36 PM |
| Alexion Pharmaceuticals' (ALXN) Buy Rating Reaffirmed at Raymond James
www.americanbankingnews.com - April 24 at 8:20 AM |
| Alexion Pharma's (ALXN) 4/26 Earnings Will Focus On Brazil - Goldman
www.streetinsider.com - April 24 at 8:18 AM |
| Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy? April 23, 2018
www.zacks.com - April 24 at 8:18 AM |
| Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 23 at 8:14 AM |
| BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil
www.reuters.com - April 22 at 8:16 AM |
| Alexion Pharma (ALXN) Defended at Leerink
www.streetinsider.com - April 22 at 8:16 AM |
| Alexion Pharmaceuticals' (ALXN) Buy Rating Reiterated at UBS
www.americanbankingnews.com - April 20 at 9:46 PM |
| UBS Reiterates Buy Rating for Alexion Pharmaceuticals (ALXN)
www.americanbankingnews.com - April 20 at 5:52 PM |
| Implications from Soliris patent ruling in Brazil likely immaterial says Alexion
seekingalpha.com - April 20 at 5:22 PM |
 | Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris (Eculizumab)
www.finanznachrichten.de - April 20 at 5:22 PM |
| Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab)
finance.yahoo.com - April 20 at 5:22 PM |
Alexion Pharmaceuticals (NASDAQ:ALXN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alexion Pharmaceuticals (NASDAQ:ALXN) Income Statement, Balance Sheet and Cash Flow Statement
Alexion Pharmaceuticals (NASDAQ ALXN) Stock Chart for Thursday, May, 24, 2018
Loading chart…
